Reduced serum IL-6 as a potential peripheral marker of amnestic mild cognitive impairment: A pilot study.

Source: PubMed, NCBI / U.S. National Library of Medicine

Mild cognitive impairment (MCI) represents an intermediate state between age-related cognitive changes and early stages of dementia. People with amnestic subtype (aMCI) show higher risks of progression to dementia due to Alzheimer's disease. In this pilot study, the aim was to investigate whether cytokines could be potential peripheral markers associated with MCI. Women were recruited in Junín city, Buenos Aires, Argentina. Their cognitive performance was evaluated using a neuropsychological battery. Serum levels of IFN-γ, IL-1β, IL-2, IL-4 and IL-6 were analyzed by ELISA, and the type 2/type 1 balance was determined. Correlations between both parameters, as well as within-group analysis cytokines levels were evaluated. After cognitive evaluation, participants were classified as healthy controls (HC: n=14) or as aMCI (n=7). IL-6 levels were significantly decreased in the aMCI group compared with HC (p=0.047). IFN-γ showed no robust correlations within the HC group but presented a strong negative correlation with IL-2 (p=0.005) and IL-4 (p=0.052) in aMCI. Several correlations were found between cytokine levels, the type 2/type 1 balance and neurocognitive tests. We concluded that IL-6 decreased levels, altered correlation in cytokine profiles, together with performance on the neuropsychological battery, may serve as potential blood-markers of amnestic mild cognitive impairment.